EGFR and non-small cell lung carcinoma: In addition, a linear correlation between tumor mutational burden (TMB) and ORRs with anti-PD-1/PD-L1 agents in multiple solid tumors, including NSCLC, has been reported [103], but EGFR-mutated NSCLCs have a lower TMB (median mutational load: 60) compared with other NSCLCs (TP53 mutated: 325; KRAS mutated: 179; STK11 mutated: 132) [104], with no relative differences between canonical exon 19 del/L858R mutations and exon 20 insertions [66].